These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23855304)

  • 21. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
    Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic fatty liver disease as a complication of insulin resistance.
    Abdelmalek MF; Diehl AM
    Med Clin North Am; 2007 Nov; 91(6):1125-49, ix. PubMed ID: 17964913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.
    Cheung O; Sanyal AJ
    Semin Liver Dis; 2008 Nov; 28(4):351-9. PubMed ID: 18956291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data.
    Yki-Järvinen H
    Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):709-14. PubMed ID: 20842026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation analysis between gene expression profile of high-fat emulsion-induced non-alcoholic fatty liver and liver regeneration in rat.
    Wang G; Li B; Hao Y; Zhi J; He C; Xu C
    Cell Biol Int; 2013 Sep; 37(9):917-28. PubMed ID: 23619824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS; Diehl AM
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease.
    Daly AK; Ballestri S; Carulli L; Loria P; Day CP
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):253-63. PubMed ID: 21476920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
    Xing LJ; Zhang L; Liu T; Hua YQ; Zheng PY; Ji G
    Eur J Pharmacol; 2011 Oct; 668(3):467-71. PubMed ID: 21839075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications.
    Targher G; Byrne CD
    Semin Thromb Hemost; 2013 Mar; 39(2):214-28. PubMed ID: 23397556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation in nonalcoholic steatohepatitis.
    Harmon RC; Tiniakos DG; Argo CK
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):189-200. PubMed ID: 21476914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
    Bosserhoff A; Hellerbrand C
    Dig Dis; 2011; 29(4):377-83. PubMed ID: 21894008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
    Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
    Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).
    Musso G; Gambino R; Cassader M
    Prog Lipid Res; 2009 Jan; 48(1):1-26. PubMed ID: 18824034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.